Introduction {#s0005}
============

Cervical cancer is the third most common type of cancer in women worldwide and persistent infection with high-risk human papillomavirus (HR-HPV) is the primary etiological agent of the disease [@bb0005; @bb0010]. Although HR-HPV infections are very common, only a small proportion (approximately 10%) become persistent, of which a subset drive the progression of occult precursors to cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3) and eventually cervical cancer [@bb0015]. Due to high sensitivity, no requirements for preservation of cell morphology and relatively low costs, HR-HPV testing is becoming the preferred method for CIN screening. However, as only a fraction of HR-HPV positive women have clinically relevant lesions, use of cytology as the primary screening test still predominates. Novel diagnostic biomarkers with high specificity are desirable as a compliment to HR-HPV testing. Development of a simple molecular triage test is particularly awaited because such a test may be more easily implemented in less developed countries and in vaginal self-collected specimens, thus leading to considerable reduction in cervical cancer deaths worldwide.

HR-HPV infection is a prerequisite for carcinogenesis but is not sufficient alone. Genetic and epigenetic changes in the host and/or viral genome affect the outcome of HR-HPV infection and identifying these key molecular changes is likely to reveal biomarkers for use in cancer prevention programs. DNA methylation has been extensively investigated as a potential biomarker of human cancers [@bb0020]. Carefully orchestrated, DNA methylation plays a crucial role for activating and silencing genes during normal development; however, its disruption contributes to carcinogenesis [@bb0025]. In cervical cancer, aberrant methylation can be detected in cervical smears up to 7 years prior to diagnosis indicating promise as a biomarker [@bb0030]. Although many human genes exhibit elevated methylation in cervical cancer, an effective testing approach exploiting these changes for triage of HR-HPV positive women requires a robust assay that can separate CIN2/3 from ≤CIN1 with an adequate and consistent differential. Quantitative methylation-specific polymerase chain reaction (QMSP) assays for *CADM1* and *MAL* [@bb0035; @bb0040; @bb0045] have shown promise as triage tools. Other combination QMSP assays of genes sets such as *EPB41L3, JAM3, TERT*, *C13ORF18* [@bb0050; @bb0055], *LMX1, PAX1, SOX1, NKX6-1* [@bb0060], and *APC, HIN-1, RARB, RASSF1A, and TWIST1* [@bb0065] are also of interest. Furthermore, some studies have identified elevated methylation of single or groups of genes, using different technologies, in both cytology samples as well as biopsy specimens [@bb0070]. In the current study, we aimed to evaluate methylation of 26 human genes in cytology samples by pyrosequencing. Genes *APC, CADM1, CCND2, CDH13, CDKN2A, CTNNB1, DAPK1, EPB41L3, ESR1*, *GSTP1, HIN1, JAM3, LMX1, MAL, PAX1, PTGS2, RARB, RASSF1, SLIT2, SOX1, SPARC, TERT* and *TWIST1* were selected as they were part of earlier described promising QMSP assays or reported as aberrant in at least two separate reports [@bb0035; @bb0040; @bb0045; @bb0050; @bb0055; @bb0060; @bb0065; @bb0070]. In addition, genes previously not investigated in cervical cancer: *DPYS, EDNRB* and *MDR1* were included as they showed interesting aberrant methylation patterns in other cancers of mucosal tissue [@bb0075; @bb0080; @bb0085]. Pyrosequencing was chosen as it gives absolute quantification of methylation [@bb0090] in contrast to the relative quantification obtained by the most commonly used method QMSP. Our aim was to measure the methylation levels of a set of promising genes on an absolute scale and to directly compare their methylation, initially in a selected set of CIN3 and normal samples. Genes that showed the best potential to separate CIN3 from normal were tested in Predictors 1 (P1) a large colposcopy referral population. The final goal was to investigate the performance of the most informative genes in a second large study Predictors 2 (P2) and to assess their potential as future triage biomarkers of HR-HPV positive women. The results of our investigations may be regarded as independent validation of the biomarkers by virtue of the use of different specimens and assays in a separate and independent laboratory.

Material and methods {#s0010}
====================

Patient cohort {#s0015}
--------------

Archived patient materials collected in two earlier studies, Predictors 1 (P1) [@bb0095] and Predictors 2 (P2) [@bb0100] were used for methylation testing. P1 and P2 comprised 1000 and 1099 women respectively attending colposcopy at Hammersmith or St Mary Hospital in London UK, during 2005--2007 (P1) or 2007--2009 (P2) because of a cytology finding of "mild dyskaryosis or worse". Women were eligible if they had been referred as a result of one or more abnormal cervical smears, were not pregnant, had not been treated previously for CIN, nor had a hysterectomy. Immediately before colposcopy, cervical specimens were obtained in PreservCyt transport medium. All analyses were based on a centrally reviewed histopathology and took the highest grade of abnormality seen in the biopsy or treatment specimen within 9 months of the initial base-line visit as the final diagnosis. The number of women with different histology findings for P1 and P2 is presented in [Supplemental table S1](#ec0005){ref-type="supplementary-material"}. 201 patients from P1 were excluded due to insufficient material for the methylation study. For identification of HR-HPV positive samples, Linear Array (Roche Molecular Systems, Inc., Pleasanton, CA, USA) results for P1 and BD HPV test (BD Diagnostics, Burlington, NC, USA) results for P2 were used.

Archived patient materials collected in two earlier studies, Predictors 1 (P1) [@bb0095] and Predictors 2 (P2) [@bb0100] were used for methylation testing. P1 and P2 comprised 1000 and 1099 women respectively attending colposcopy at Hammersmith or St Mary Hospital in London UK, during 2005--2007 (P1) or 2007--2009 (P2) because of a cytology finding of "mild dyskaryosis or worse". Women were eligible if they had been referred as a result of one or more abnormal cervical smears, were not pregnant, had not been treated previously for CIN, nor had a hysterectomy. Immediately before colposcopy, cervical specimens were obtained in PreservCyt transport medium. All analyses were based on a centrally reviewed histopathology and took the highest grade of abnormality seen in the biopsy or treatment specimen within 9 months of the initial base-line visit as the final diagnosis. The number of women with different histology findings for P1 and P2 is presented in Supplemental table S1. 201 patients from P1 were excluded due to insufficient material for the methylation study. For identification of HR-HPV positive samples, Linear Array (Roche Molecular Systems, Inc., Pleasanton, CA, USA) results for P1 and BD HPV test (BD Diagnostics, Burlington, NC, USA) results for P2 were used.

All women received a patient information sheet explaining the study and provided written consent. Approvals were obtained from the relevant local research ethics committees.

DNA isolation and bisulfite conversion {#s0020}
--------------------------------------

300 μl of PreservCyt was centrifuged at 13 200 rpm for 2 min and the pellet was resuspended in 200 μl PBS. The genomic DNA was extracted with QIAamp DNA Mini Kit (Qiagen Inc., Hilden, Germany) following the spin protocol recommended by the manufacturer except that DNA was eluted in 60 μl AE buffer. 250 ng of DNA was used in the bisulfite conversion reactions where unmethylated cytosines were converted to uracil with the EZ DNA methylation kit (Zymo research, Irvine, CA) according to manufacturer\'s instructions.

The methylation assays {#s0025}
----------------------

The methylation assays for *APC, CCND2, CDH13, CDKN2A, DAPK1, DPYS, EDNRB, ESR1, GSTP1, HIN1, MAL, MDR1, PTGS2, RARB, RASSF1, SLIT2* and *TWIST1* were previously described [@bb0105]. The remaining assays are presented in [Supplemental table S2](#ec0010){ref-type="supplementary-material"}. All primers were designed using PyroMark Assay Design software version 2.0.1.15 (Qiagen). The assays were designed to avoid any overlapping of CpG positions and aimed to investigate the same CpG positions or those in close proximity to CpG sites previously investigated for a gene. To provide the internal control for total bisulfite conversion, a non CG cytosine was included. Although genes *C13ORF18* and *NKX6-1* were part of combination QMSP assays of interest [@bb0050] we were not able to design corresponding pyrosequencing assays due to high CpG density. Polymerase chain reaction (PCR) assays were performed as described in the footnote to [Supplemental table 2](#ec0010){ref-type="supplementary-material"}. The presence of the correct amplicon was confirmed on Qiaxel (Qiagen) and pyrosequencing was done as previously described [@bb0105]. All runs included standard curves as positive controls, of 0%, 50% and 100% methylated human DNA and a non-template control.

The methylation assays for *APC, CCND2, CDH13, CDKN2A, DAPK1, DPYS, EDNRB, ESR1, GSTP1, HIN1, MAL, MDR1, PTGS2, RARB, RASSF1, SLIT2* and *TWIST1* were previously described [@bb0105]. The remaining assays are presented in Supplemental table S2. All primers were designed using PyroMark Assay Design software version 2.0.1.15 (Qiagen). The assays were designed to avoid any overlapping of CpG positions and aimed to investigate the same CpG positions or those in close proximity to CpG sites previously investigated for a gene. To provide the internal control for total bisulfite conversion, a non CpG cytosine was included. Although genes *C13ORF18* and *NKX6-1* were part of combination QMSP assays of interest [@bb0050] we were not able to design corresponding pyrosequencing assays due to high CpG density. Polymerase chain reaction (PCR) assays were performed as described in the footnote to Supplemental table 2. The presence of the correct amplicon was confirmed on Qiaxel (Qiagen) and pyrosequencing was done as previously described [@bb0105]. All runs included standard curves as positive controls, of 0%, 50% and 100% methylated human DNA and a non-template control.

Data analysis {#s0030}
-------------

Mean methylation of the investigated CpG positions, 3--6 per each gene, was used for all the analyses. Median methylation of genes in CIN2/3 and ≤CIN1 tissues was compared using the Mann--Whitney *U* test. For random selection of 40 samples from P1, a computer random number generator was used. To account for the high number of genes analyzed on the initial sample set, the Benjamin and Hochberg step-up procedure for controlling false discovery rate (FDR) was applied with an FDR limit of 5% [@bb0110]. Any failed assays were excluded from the analysis. Raw *p*-values are presented in the text and tables with footnotes indicating *p*-values significant at 5% FDR. Spearman\'s rho correlation coefficient was estimated for methylation levels of the 6 genes in the entire P1 data set. Each gene was evaluated by receiver operating characteristics (ROCs) analyses, area under the curve (AUC) was the main measure used to assess the ability of genes to classify high grade disease. Methylation data from cancers were excluded from all analysis, but are presented in the supplemental data. Univariate and multivariate analysis was done using logistic regression models and compared by likelihood ratio (LR) and χ^2^ statistics. STATA v12 and GraphPad Prism v5.03 were used for statistical analysis and illustrations.

Results {#s0035}
=======

Methylation of 26 genes in 40 patients from the Pilot Set {#s0040}
---------------------------------------------------------

The methylation of 26 genes was measured in the pilot set comprising 20 CIN3 and 20 normal controls, all were HR-HPV positive and randomly selected from the P1 study. No assays failed in the pilot set. Overall the methylation of genes was low with 14 genes---*JAM3, GSTP1, CDKN2A, APC, HIN1, RARB, RASSF1A*, *TWIST1, ESR1, CDH13, SPARC*, *PTGS2, CTNNB1 and CCND2* showing median methylation ≤ 1% in both groups ([Supplemental table 3](#ec0015){ref-type="supplementary-material"}), these were excluded from further consideration. Eight genes: *EPB41L3, EDNRB*, *DPYS, LMX1, CADM1, TERT, PAX1* and *MDR1* showed elevated methylation in CIN3 and were individually significant at *α* = 0.05 ([Supplemental table 3](#ec0015){ref-type="supplementary-material"}). However, after correction for multiple comparisons, only *EPB41L3* (*p* \< 0.0001) and *EDNRB* (*p* = 0.0004) remained significant and consequently they were tested in the entire P1 study. In addition, *LMX1* and *DPYS* showed relatively high methylation (3--6%) with good ability to separate normal from CIN3 with AUC \> 0.7 ([Table 1](#t0005){ref-type="table"}). Thus, these genes were also investigated in the entire P1 cohort. Additionally, *MAL* and *CADM1* were tested in the P1 study because these two genes were extensively evaluated in earlier reports and shown as particularly promising methylation biomarkers. In total, 6 genes were tested in all remaining (759) patients from the P1 cohort.

The methylation of 26 genes was measured in the pilot set comprising 20 CIN3 and 20 normal controls, all were HR-HPV positive and randomly selected from the P1 study. No assays failed in the pilot set. Overall the methylation of genes was low with 14 genes---*JAM3, GSTP1, CDKN2A, APC, HIN1, RARB, RASSF1A*, *TWIST1, ESR1, CDH13, SPARC*, *PTGS2, CTNNB1 and CCND2* showing median methylation ≤ 1% in both groups (Supplemental table 3), these were excluded from further consideration. Nine genes: *EPB41L3, EDNRB*, *DPYS, CADM1, LMX1, JAM3, TERT, PAX1* and *MDR1* showed elevated methylation in CIN3 and were individually significant at *α* = 0.05 (Supplemental table 3). However, after correction for multiple comparisons, only *EPB41L3* (*p* \< 0.0001) and *EDNRB* (*p* = 0.0004) remained significant and consequently they were tested in the entire P1 study. In addition, *LMX1* and *DPYS* showed relatively high methylation (3--6%) with good ability to separate normal from CIN3 with AUC \> 0.7 ([Supplemental Table 3](#ec0015){ref-type="supplementary-material"}). Thus, these genes were also investigated in the entire P1 cohort. Additionally, *MAL* and *CADM1* were tested in the P1 study because these two genes were extensively evaluated in earlier reports and shown as particularly promising methylation biomarkers. In total, 6 genes were tested in all remaining (759) samples available from the P1 cohort.

Methylation of EPB41L3, EDNRB, DPYS, LMX1, CADM1 and MAL in the P1 study {#s0045}
------------------------------------------------------------------------

The methylation of the 6 selected genes was measured in all available P1 samples and was analyzed separately for 572 HR-HPV positive ([Table 1](#t0005){ref-type="table"}) and 217 negative samples. The success rates for all the methylation assays was 97.0--99.9%. In HR-HPV positive patients, Mann--Whitney *U* test indicated that methylation was elevated in CIN2/3 for all 6 genes (*p* \< 0.001). Particularly, *EPB41L3* showed the best separation of high grade lesions from those with ≤ CIN1 with AUC 0.73 (95%CI 0.68--0.77). Although *EDNRB* was second best at separating the diagnostic groups with AUC 0.67 (95%CI 0.62--0.71), its methylation was also most highly correlated to methylation of *EPB41L3* ([Table 2](#t0010){ref-type="table"}). The AUC for *DPYS, LMX1*, *MAL* and *CADM1* were 0.65 (95%CI 0.6--0.69), 0.63 (95%CI 0.58--0.68), 0.61 (95%CI 0.56--0.66) and 0.58 (95%CI 0.53--0.63) respectively. Except for *DPYS* and *MAL,* methylation of all genes showed significant correlation to methylation of the other genes (*p* \< 0.001) ([Table 2](#t0010){ref-type="table"}). A logistic regression model was used to explore the pairwise predictive power of the methylation of the 6 genes ([Supplemental table S3](#ec0015){ref-type="supplementary-material"}). In a multivariate model with *EPB41L3*, other genes did not add significant information for identifying high grade disease; however *DPYS* was the strongest gene among the remaining 5 ([Supplemental table S4](#ec0020){ref-type="supplementary-material"}). Therefore, *EPB41L3* and *DPYS* were selected for investigation in all HR-HPV positive samples (884) in the P2 cohort. Although pre-selected due to its high profile in publications, *CADM1* performed the poorest amongst the six genes, had the lowest AUC, median methylation ([Supplemental Fig. S1](#ec0025){ref-type="supplementary-material"}), and had the lowest univariate LR-χ^2^ ([Supplemental table S4](#ec0020){ref-type="supplementary-material"}). *CADM1* was therefore excluded from further testing. *MAL* was however, taken forward for further evaluation.

The methylation of the 6 selected genes was measured in all available P1 samples and was analyzed separately for 572 HR-HPV positive ([Table 1](#t0005){ref-type="table"}) and 217 negative samples. The success rates for all the methylation assays was 97.0--99.9%. In HR-HPV positive patients, Mann--Whitney *U* test indicated that methylation was elevated in CIN2/3 for all 6 genes (*p* \< 0.001). Particularly, *EPB41L3* showed the best separation of high grade lesions from those with ≤CIN1 with AUC 0.73 (95%CI 0.68--0.77). Although *EDNRB* was second best at separating the diagnostic groups with AUC 0.67 (95%CI 0.62--0.72), its methylation was also most highly correlated to methylation of *EPB41L3* ([Table 2](#t0010){ref-type="table"}). The AUC for *DPYS, LMX1*, *MAL* and *CADM1* were 0.65 (95%CI 0.60--0.69), 0.63 (95%CI 0.58--0.68), 0.62 (95%CI 0.57--0.67) and 0.58 (95%CI 0.53--0.62) respectively. Except for *DPYS* and *MAL,* methylation of all genes showed significant correlation to methylation of the other genes (*p* \< 0.001) ([Table 2](#t0010){ref-type="table"}). A logistic regression model was used to explore the pairwise predictive power of the methylation of the 6 genes (Supplemental table S3). In a multivariate model with *EPB41L3*, other genes did not add substantial information for identifying high grade disease; however *DPYS* was the strongest gene among the remaining 5 (Supplemental table S4). Therefore, *EPB41L3* and *DPYS* were selected for investigation in all HR-HPV positive samples (884) in the P2 cohort. Although pre-selected due to its high profile in publications, *CADM1* performed the poorest amongst the six genes, had the lowest AUC, median methylation (Supplemental Fig. S1), and had the lowest univariate LR-χ^2^ (Supplemental table S4). *CADM1* was therefore excluded from further testing. *MAL* was however, taken forward for further evaluation.

In HR-HPV negative patients, *EPB41L3* (*p* = 0.02) and *DPYS* (*p* = 0.04) showed significantly elevated methylation in the 10 CIN2/3 cases while the other genes did not ([Fig. 1](#f0005){ref-type="fig"}A).

Internal validation of EPB41L3 and DPYS genes in P2 HR-HPV positive samples {#s0050}
---------------------------------------------------------------------------

*EPB41L3*, *DPYS* and *MAL* showed a similar distribution of methylation in ≤ CIN1 and CIN2/3 in both studies ([Fig. 1](#f0005){ref-type="fig"}b). The combined methylation data from all HR-HPV positive P1 and P2 samples stratified by histology groups: normal, CIN1, CIN2, CIN3 and cancer is shown in [Supplemental Fig. S1](#ec0025){ref-type="supplementary-material"}. The methylation in cancer tissues was highest, followed by CIN3.

*EPB41L3*, *DPYS* and *MAL* showed a similar distribution of methylation in ≤CIN1 and CIN2/3 in both studies ([Fig. 1](#f0005){ref-type="fig"}B). The combined methylation data from all HR-HPV positive P1 and P2 samples stratified by histology groups: normal, CIN1, CIN2, CIN3 and cancer is shown in Supplemental Fig. S1. The methylation in cancer tissues was highest, followed by CIN3.

Based on the methylation data from the P1 specimens, a cut-off to reach a minimum of 90% sensitivity was selected for the 3 genes: *EBP41L3* = 0.9, *DPYS* = 2.7 and *MAL* = 0.5 and then applied to data collected in P2 ([Table 3](#t0015){ref-type="table"}). The AUC for all three genes were reproducible in the two studies and specificity and sensitivity at the selected cut-off indicated that all three genes preformed similarly in P1 and P2 ([Table 3](#t0015){ref-type="table"}). *EPB41L3* was the best at separating CIN2/3 while *MAL* was the poorest classifier. Furthermore *EPB41L3* showed the best ability to identify CIN2/3 in both the P1 and P2 cohort with similar AUC of 0.73 (95% CI 0.68--0.77) and 0.69 (0.65--0.73) respectively ([Fig. 2](#f0010){ref-type="fig"}).

Discussion {#s0055}
==========

The absolute methylation of 26 genes in 20 normal cervical scrapes compared to 20 scrapes from women diagnosed with CIN3 showed elevated methylation of *EBP41L3, EDNRB, DPYS, CADM1, LMX1, TERT, PAX1 and MDR1* (*p* \< 0.05) ([Supplemental table 3](#ec0015){ref-type="supplementary-material"}). However, after adjustment for multiple testing in the pilot, only *EPB41L3* and *EDNRB* remained significant. To further investigate the biomarker potential of these genes, their methylation as well as *DPYS, LMX1, CADM1* and *MAL* was measured in specimens from the P1 study. Although methylation of *MAL* did not appear interesting in the initial set of 40, it was investigated in the entire P1 cohort because in combination with *CADM1*, a QMSP assay based on these two genes has been repeatedly shown as promising by a team in the Netherlands [@bb0035; @bb0040; @bb0045]. Similarly, a different group from Taiwan suggested [@bb0060] a four gene model including *LMX1, SOX1, PAX1, NKX6-1* for a QMSP assay. Although we were not able to obtain an assay for *NKX6-1*, out of the remaining 3 genes, *LMX1* showed the best separation of CIN3 from normal tissues ([Supplemental table 3](#ec0015){ref-type="supplementary-material"}) and therefore was also investigated in the P1 specimens. Overall, the methylation of the 26 genes was low, with median values less than 10%. For 14 genes median methylation of less than 1% was observed ([Supplemental table 3](#ec0015){ref-type="supplementary-material"}); with such low methylation values there is an increased possibility of measurement errors and these genes were not further investigated, regardless of whether or not they were previously shown to have interesting potential [@bb0065; @bb0070]. A possible explanation for the disagreement in results between our study and those in earlier reports is that the small absolute differences we saw by pyrosequencing may be increased by primer-biased QMSP assays which give data in relative terms. Another possibility is that some of the CpG sites investigated were different from those previously reported due to assay design requirements. Although in close proximity, methylation can vary in different CpGs that are part of the same CpG island [@bb0115]. *DAPK1* is an example where our pyrosequencing assay was approximately 200 bp downstream of the CpG sites most commonly investigated by other methods. *DAPK1* has repeatedly been suggested to have significantly altered methylation in high grade lesions in cancers [@bb0070]. Recently, this gene was proposed as a complimentary test to HPV methylation assays to provide a comprehensive classifier for identification of CIN2 + by use of the bisulfite sequencing method [@bb0120]. Although our assay did not show any differences in *DAPK1* methylation ([Table 1](#t0005){ref-type="table"}), pyrosequencing or QMSP are more likely tests than bisulfite sequencing for use in a clinical setting and it is possible that pyrosequencing assays for *EPB41L3* and HPV [@bb0125] can provide a similar combination test as *DAPK1* and HPV.

The absolute methylation of 26 genes in 20 normal cervical scrapes compared to 20 scrapes from women diagnosed with CIN3 showed elevated methylation of *EBP41L3, EDNRB, DPYS, CADM1, LMX1, JAM3, TERT, PAX1 and MDR1* (*p* \< 0.05) (Supplemental table 3). However, after adjustment for multiple testing in the pilot, only *EPB41L3* and *EDNRB* remained significant. To further investigate the biomarker potential of these genes, their methylation as well as *DPYS, LMX1, CADM1* and *MAL* was measured in specimens from the P1 study. Although methylation of *MAL* did not appear interesting in the initial set of 40, it was investigated in the entire P1 cohort because in combination with *CADM1*, a QMSP assay based on these two genes has been repeatedly shown as promising by a team in the Netherlands [@bb0035; @bb0040; @bb0045]. Similarly, a different group from Taiwan suggested [@bb0060] a four gene model including *LMX1, SOX1, PAX1, NKX6-1* for a QMSP assay. Although we were not able to obtain an assay for *NKX6-1*, out of the remaining 3 genes, *LMX1* showed the best separation of CIN3 from normal tissues (Supplemental table 3) and therefore was also investigated in the P1 specimens. Overall, the methylation of the 26 genes was low, with median values less than 10%. For 14 genes median methylation of less than 1% was observed in CIN3 (Supplemental table 3); with such low methylation values there is an increased possibility of measurement errors and these genes were not further investigated, regardless of whether or not they were previously shown to have interesting potential [@bb0065; @bb0070]. A possible explanation for the disagreement in results between our study and those in earlier reports is that the small absolute differences we saw by pyrosequencing may be increased by primer-biased QMSP assays which give data in relative terms. Another possibility is that some of the CpG sites investigated were different from those previously reported due to assay design requirements. Although in close proximity, methylation can vary in different CpGs that are part of the same CpG island [@bb0115]. *DAPK1* is an example where our pyrosequencing assay was approximately 200 bp downstream of the CpG sites most commonly investigated by other methods. *DAPK1* has repeatedly been suggested to have significantly altered methylation in high grade lesions in cancers [@bb0070]. Recently, this gene was proposed as a complimentary test to HPV methylation assays to provide a comprehensive classifier for identification of CIN2 + by use of the bisulfite sequencing method [@bb0120]. Although our assay did not show any differences in *DAPK1* methylation ([Supplemental Table 3](#ec0015){ref-type="supplementary-material"}), pyrosequencing or QMSP are more likely tests than bisulfite sequencing for use in a clinical setting and it is possible that pyrosequencing assays for *EPB41L3* and HPV [@bb0125] can provide a similar combination test as *DAPK1* and HPV.

We included testing of *MAL* in our study as a pre-selected gene because of the strong data by QMSP that it is a useful biomarker for CIN2/3. Although we investigated the same CpGs as in the earlier QMSP studies *MAL* did not show any promise as a classifier in our pyrosequencing-based methylation assay indicating important differences between the methods used and possibly also samples used. The current main weakness of the proposed *CADM1* and *MAL* QMSP assay is that it has not been validated by different groups and in different study populations.

Our primary goal was to investigate the biomarker potential of a relatively large set of candidate human genes for pyrosequencing methylation assays to triage HR-HPV positive women. However, in P1, we also assessed the biomarker utility of the genes in HR-HPV negative women. While, all 6 investigated genes showed significantly elevated methylation in 208 CIN2/3 HR-HPV positive samples, elevated methylation was observed only for *EPB41L3* and *DPYS* in the 10 CIN2/3 HR-HPV negative women ([Fig. 1](#f0005){ref-type="fig"}A). This suggests that measurement of methylation of some genes might be useful to identify women who are at risk of developing cervical cancer irrespective of HR-HPV status.

A combination of the collected methylation data from both P1 and P2 HR-HPV positive women showed that methylation was several fold higher in cancers for all investigated genes ([Supplemental fig. S1](#ec0025){ref-type="supplementary-material"}). Although the optimal cut-off for cancer was not established for *EPB41L3,* this assay may be useful for cancer detection with an observed 100% sensitivity and 91% specificity versus the group of CIN2/3 plus [\<]{.ul} CIN1in the P1 specimens (data not shown). It is noteworthy that the cut-offs for classification of cancers were higher than those of CIN2/3. This demonstrates that when searching for diagnostic biomarkers able to distinguish low from high grade precursor lesions, it is reasonable to exclude the cancers from the analyses to avoid potential skewing of cut-offs, it appears that virtually all the cancers may be detected regardless of the best final cut-offs chosen to detect the CIN2/3.

A combination of the collected methylation data from both P1 and P2 HR-HPV positive women showed that methylation was several fold higher in cancers for all investigated genes (Supplemental fig. S1). Although the optimal cut-off for cancer was not established for *EPB41L3,* this assay may be useful for cancer detection with an observed 100% sensitivity and 91% specificity versus the group of CIN2/3 plus [\<]{.ul}CIN1 in the P1 specimens (data not shown). It is noteworthy that the cut-offs for classification of cancers were higher than those of CIN2/3. This demonstrates that when searching for diagnostic biomarkers able to distinguish low from high grade precursor lesions, it is reasonable to exclude the cancers from the analyses to avoid potential skewing of cut-offs, it appears that virtually all the cancers may be detected regardless of the best final cut-offs chosen to detect the CIN2/3.

*EPB41L3*, encoding the DAL-1 protein, was originally identified as a down-regulated tumor suppressor in lung adenocarcinoma [@bb0130] with later evidence emerging that its down-regulations may be attributed to promoter hypermethylation [@bb0135]. Loss of DAL-1 and its associated tumor suppressor activity have also been seen in breast [@bb0140], prostate cancer [@bb0145] and meningiomas [@bb0150]. To the best of our knowledge, there are no reports illustrating the expression of DAL-1 in cervical cancer and taking into consideration its role in other cancers as well as the aberrant methylation seen in our study and reported by others, further studies are warranted.

Elevated methylation in HPV16 L1 in CIN2/3 lesions is becoming increasingly evident [@bb0155; @bb0160; @bb0165]. Recently, we showed that a classifier based on methylation in HPV16 L1 and L2 may be useful for identifying women with CIN2/3 [@bb0125]. Other HPV types such as HPV18, HPV31 and HPV45 have also shown similar characteristics [@bb0120; @bb0170; @bb0175]. The feasibility of including *EPB41L3* in a QMSP assay with other genes has already been shown in cervical scrapes [@bb0050] and in cervico-vaginal lavages obtained by a self-sampling [@bb0055]. The potential for success of methylation classifiers in self-collected specimens increases their value and could lead to important improvements in preventing cervical cancer deaths, particularly in less developed regions of the world.

Some limitations of our study are that we used a different assay than most prior investigators and also that we used archived specimens from women referred to colposcopy. Conversely the limitations also provide some advantages in that our results are a stronger validation of the intrinsic value of the identified biomarkers because the biomarker diagnostic potential is preferably not limited to just certain assays. Furthermore, we were able to investigate methylation in a large group of CIN2 +. Another limitation is that our study did not include an assessment of all possible CpG sites in the gene promoters which requires more powerful methods such as directed deep sequencing. With respect to other potential triage methods for HR-HPV positive women such as reflex cytology, p16 staining and HPV genotyping, our results are quite modest and the best gene *EPB41L3* provided an AUC of 0.69 ([Table 3](#t0015){ref-type="table"}) in the validation set. Therefore we anticipate the need to improve the performance of our current gene assay or perhaps to use *EPB41L3* in combination with other biomarkers such as methylation of HPV16 and other HR-HPV [@bb0120; @bb0125].

In summary, the measurement of methylation of several human genes may be considered for assays to separate CIN2/3 from normal women. Methylation of *EPB41L3* was low in the ≤CIN1 group, was significantly elevated in CIN2/3 and was highest in cancers; this gene was the best classifier in the set of genes evaluated here. Our pyrosequencing assay using *EPB41L3* accurately detected CIN2/3 and cervical cancers in two different sets of specimens and looks suitable for further evaluation both alone and in combination with other viral and/or human genes as a potential molecular approach to triage of HR-HPV positive women.

The following are the supplementary data related to this article.Supplemental table S1Summary of worst reviewed histology (WRH) in patients analyzed from the P1 and P2 study.Supplemental table S2PCR assay^1^ and primer details; forward (F), reverse (R) and sequencing (s) primers for additionally created assays are shown giving the size and position of the amplicons as well as the number of investigated CGs for each gene.Supplemental table S3The median methylation %, interquartile range (IQR) and area under the curve (AUC) in the pilot set of 20 normal and 20 CIN3 for each of the 26 investigated genes. Mann--Whitney *U* test identified 9 genes (bold) with *p*-values \< 0.05.Supplemental table S4Univariate LR-χ2 and multivariate LR-χ2 demonstrating the value of information added by the next gene to each logistic regression model.Supplemental Fig. S1Distribution of methylation stratified by histological groups: normal, CIN1, CIN2, CIN3 and cancer. A) The methylation of EPB41L3, DPYS and MAL in all analyzed HR-HPV positive samples from P1 and P2 showed highest methylation of cancers. For better visualisation of the low methylation results, 2 outliers are not shown \`here, one at 70% EPB41L3 methylation in a normal tissue from P2 and one at 91% DPYS methylation in a normal tissue from P1. B) The methylation of *EDNRB, LMX1* and *CADM1* in HR-HPV positive samples from P1 cohort also showed highest methylation in cancers. Whiskers of the boxplot mark the 5th and 95th percentiles, the box 25th percentile, median and 75 percentile, while extreme values are shown by (•).

Supplementary data to this article can be found online at [http://dx.doi.org/10.1016/j.ygyno.2014.02.001](10.1016/j.ygyno.2014.02.001){#ir0005}.
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![The distribution of methylation in HR-HPV negative and positive samples. A) Comparison of methylation distribution of 6 genes in 207 HR-HPV negative controls (white) and 10 CIN2/3 (grey) in the P1 study. *EPB41L3* (*p* = 0.023) and *DPYS* (p = 0.043) showed elevated methylation in CIN2/3 while *CADM1* (*p* = 0.051), *MAL* (*p* = 0.810) and *LMX1* (*p* = 0.177) did not. B) Comparison of *EPB41L3*, *DPYS* and *MAL* methylation distribution in HR-HPV positive \<CIN1 controls (white) and CIN2/3 (grey) from P1 and P2 cohort. Significantly elevated methylation was observed in CIN2/3 group for all three genes in both studies (*p* \< 0.0001). Numbers of patients in each group are available in Supplemental table S1. For better visualisation of the low methylation results, 2 outliers are not shown, one at 70% *EPB41L3* methylation in a normal tissue from P2 and one at 91% *DPYS* methylation in a normal tissue from P1. Whiskers of the boxplot mark the 5th and 95th percentiles, the box 25th percentile, median and 75 percentile, while extreme values are shown by (•).](gr1){#f0005}

![The comparison of ROC curves in P1 and P2 for *EPB41L3.*](gr2){#f0010}

###### 

Median methylation % and interquartile range (IQR), area under the curve (AUC) and 95% confidence intervals (CI), and Mann--Whitney *U* test *P* values for the 6 top genes measured in the HR-HPV positive P1 specimens, comparing women diagnosed with histological CIN2/3 to women diagnosed with [\<]{.ul}CIN1 (includes CIN1 and normal).

  -----------------------------------------------------------------------------------------------------------------------------
  GENE        [\<]{.ul}CIN1   CIN2/3     AUC     95%CI      *P*[a](#tf0005){ref-type="table-fn"}                
  ----------- --------------- ---------- ------- ---------- -------------------------------------- ------------ ---------------
  *EPB41L3*   1.4\            1.0--2.5   3.3\    1.4--7.6   0.73                                   0.68--0.77   2.8\*10^− 19^
              (363)                      (208)                                                                  

  *EDNRB*     1.5\            0.8--2.6   3.3\    1.5--6.1   0.67                                   0.62--0.72   3.4\*10^− 12^
              (363)                      (208)                                                                  

  *DPYS*      4.6\            3.2--5.8   5.4\    4.2--6.6   0.65                                   0.61--0.70   7.4\*10^− 10^
              (364)                      (208)                                                                  

  *LMX1*      3.9\            3.3--4.6   4.6\    3.6--7.1   0.63                                   0.58--0.68   3.4\*10^− 07^
              (348)                      (193)                                                                  

  *MAL*       2.4\            1.6--3.5   3.2\    2.1--4.8   0.62                                   0.57--0.67   2.8\*10^− 06^
              (363)                      (206)                                                                  

  *CADM1*     1.6\            0.9--3.0   2.6\    1.1--5.3   0.58                                   0.53--0.62   1.1\*10^− 03^
              (357)                      (205)                                                                  
  -----------------------------------------------------------------------------------------------------------------------------

Indicates *P* values not adjusted for multiple testing, all genes remained significantly associated with CIN2/3 (*P* \< 0.05) at a false discovery rate of 5%.

The medians and IQR exclude specimens where the methylation assay failed or gave a value of 0%. The numbers of specimens where methylation was either (failed, or 0%) in [\<]{.ul}CIN1 for each of the genes were as follows: E*PB41L3* (1, 68); *EDNRB* (1, 131); *DPYS* (0, 12); *LMX1* (16, 21); *MAL* (1, 43); *CADM1* (7, 211), respectively. For CIN2/3 the values for failed or 0% methylation were *EPB41L3* (0, 12); *EDNRB* (0, 48); *DPYS* (0, 0); *LMX1* (15, 9); *MAL* (2, 21); *CADM1* (3, 101), respectively.

*n* indicates the number of specimens of each histological category tested for each gene.

###### 

Spearman correlation coefficient showing the level of correlation of gene methylation in P1 specimens.

              *CADM1*   *MAL*    *DPYS*   *EDNRB*   *EPB41L3*   *LMX1*
  ----------- --------- -------- -------- --------- ----------- --------
  *CADM1*     1.00                                              
  *MAL*       0.19      1.00                                    
  *DPYS*      0.27      − 0.02   1.00                           
  *EDNRB*     0.26      0.55     0.19     1.00                  
  *EPB41L3*   0.27      0.45     0.20     0.58      1.00        
  *LMX1*      0.26      0.38     0.28     0.42      0.40        1.00

###### 

Univariate analysis of the ability of three human genes to separate ≤CIN1 from CIN2/3 in HR-HPV positive samples. The number of patients with successful methylation measurement in each group and study is presented. The AUCs with 95%CI, sensitivity and specificity in P1 and P2 are compared at a cut-off selected in the P1 study to reach minimum 90% sensitivity.

                                                   *EPB41L3*    *DPYS*       *MAL*                                  
  ------------------------------------------------ ------------ ------------ ------------ ------------ ------------ ------------
  No.[a](#tf0020){ref-type="table-fn"} of ≤CIN1    363          535          364          541          363          543
  No.[b](#tf0025){ref-type="table-fn"} of CIN2/3   208          323          208          330          206          326
  AUC                                              0.73         0.69         0.65         0.64         0.62         0.59
  95%CI                                            0.68--0.77   0.65--0.73   0.61--0.70   0.61--0.68   0.57--0.67   0.55--0.63
  Cut-off                                          0.9          2.7          0.5                                    
  Sensitivity                                      90           85           90           82           90           94
  Specificity                                      31           31           22           31           12           6

Total number of ≤CIN1 in P1 and P2 was 364 and 545 respectively.

Total number of CIN2/3 in P1 and P2 was 208 and 330 respectively.

[^1]: These authors contributed equally to this work.
